| __timestamp | Gilead Sciences, Inc. | Novartis AG |
|---|---|---|
| Wednesday, January 1, 2014 | 2983000000 | 14993000000 |
| Thursday, January 1, 2015 | 3426000000 | 14247000000 |
| Friday, January 1, 2016 | 3398000000 | 14192000000 |
| Sunday, January 1, 2017 | 3878000000 | 14997000000 |
| Monday, January 1, 2018 | 4056000000 | 16471000000 |
| Tuesday, January 1, 2019 | 4381000000 | 14369000000 |
| Wednesday, January 1, 2020 | 5151000000 | 14197000000 |
| Friday, January 1, 2021 | 5246000000 | 14886000000 |
| Saturday, January 1, 2022 | 5673000000 | 14253000000 |
| Sunday, January 1, 2023 | 6090000000 | 12489000000 |
| Monday, January 1, 2024 | 6091000000 | 12566000000 |
Unveiling the hidden dimensions of data
In the ever-evolving pharmaceutical industry, understanding the financial strategies of leading companies is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Novartis AG and Gilead Sciences, Inc. from 2014 to 2023. Over this period, Novartis consistently outspent Gilead, with its SG&A expenses peaking at approximately $16.5 billion in 2018. In contrast, Gilead's expenses showed a steady upward trend, culminating in a 104% increase from 2014 to 2023. This divergence highlights Novartis's aggressive market strategies and Gilead's gradual expansion. Such insights are invaluable for investors and industry analysts seeking to understand the financial health and strategic priorities of these pharmaceutical titans.
Gross Profit Trends Compared: Novartis AG vs Gilead Sciences, Inc.
Operational Costs Compared: SG&A Analysis of Novartis AG and Pfizer Inc.
Novartis AG and Amgen Inc.: SG&A Spending Patterns Compared
SG&A Efficiency Analysis: Comparing Novartis AG and Intra-Cellular Therapies, Inc.
Novartis AG and Blueprint Medicines Corporation: SG&A Spending Patterns Compared
Novartis AG vs Alkermes plc: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for Gilead Sciences, Inc. and Sarepta Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Gilead Sciences, Inc. and MorphoSys AG
Comparing SG&A Expenses: Gilead Sciences, Inc. vs Perrigo Company plc Trends and Insights
Who Optimizes SG&A Costs Better? Gilead Sciences, Inc. or Dynavax Technologies Corporation
Gilead Sciences, Inc. vs Amphastar Pharmaceuticals, Inc.: SG&A Expense Trends
Operational Costs Compared: SG&A Analysis of Gilead Sciences, Inc. and Evotec SE